Innovation Pharmaceuticals Inc (IPIX)

[FlashingLeather]

To paraphrase Leo...."yes, yes, and yes"...

Larger double blind placebo controlled trials like the Prurisol psoriasis trial will garner higher interest then a early PoC.

Perhaps it's time to review developmental biotech investing axiom #BR-549 which states:

Trial Design Matters

from which one can conclude:

interim P >>> topline B-UP

because:

|ph2b||double-blind||placebo control||n=189| >>> |ph2a||open-label||PoC||n=17|

Tack on the magnitude of uncertainty to be resolved and the significance to IPIX's current value maximization strategy and you have an much, much bigger event on the horizon.